Identify the strongest counterarguments to Figure AI's success — including historical failures of robotics startups…

Figure AI faces substantial headwinds rooted in robotics' long track record of overpromising and underdelivering at scale. Historical failures like Rethink Robotics illustrate how even innovative cobot pioneers can collapse when sales expectations miss and commercialization lags.[1][2]

Rethink closed in 2018 after an acquisition fell through and cash ran out; its Baxter and Sawyer robots, while pioneering safe collaboration, proved too slow and imprecise for demanding industrial use, with sales far below forecasts. Sarcos, after public listing via SPAC, pivoted entirely away from hardware in 2023–2024—suspending exoskeleton and industrial robot commercialization, laying off ~150 employees, and shifting to AI software—because its complex, expensive hardware could not achieve profitable scale or reliable field performance.[3][4]

These cases show the mechanism: high fixed costs for custom actuators, sensors, and integration combine with narrow real-world tolerance to create unsustainable burn rates before recurring revenue materializes. The implication is that Figure’s $39B valuation and aggressive timelines risk repeating the pattern unless it closes the gap between pilot hype and profitable, repeatable deployments faster than predecessors.

Demos continue to outpace reliable, transferable real-world performance. Figure’s recent livestreams of package-sorting shifts (8–67 hours claimed with minimal intervention) look impressive in controlled loops, yet experts and observers note visible pauses, misplaced packages, slower-than-human speeds, and setups where the same items cycle repeatedly rather than handling dynamic warehouse variability.[5][6]

Broader industry analysis highlights the core issue: policies trained on narrow distributions or simulation fail when encountering out-of-distribution objects, lighting changes, or slight environmental perturbations; one 95% reliable step compounds across 100 sequential actions into <1% end-to-end success.[7][8]

Even Figure’s CEO has described an “open-ended state space” and “never-ending problem city.” This gap matters because customers (BMW pilots, logistics trials) quickly discover that lab or short-shift success does not translate to 24/7 uptime with minimal human oversight—precisely the economics required to justify high capital outlays.

Hardware cost and manufacturability remain structural bottlenecks. Figure has publicly detailed redesigning its entire robot from prototype (high part count, CNC-machined components) to more scalable processes, acknowledging that legacy supply chains for actuators, sensors, and batteries are immature.[9]

Current analyst estimates place Figure units at $30,000–$150,000, while average humanoid selling prices in 2024 hovered near $200,000.[10][11] Scaling to thousands of units requires capital-intensive retooling and yield improvements that have historically drained robotics startups before volume economics kick in. The implication is that any delay in hitting sub-$25,000 viable pricing (or proving 90%+ uptime at that cost) erodes the unit economics that justify Figure’s valuation.

Chinese competitors are already shipping at dramatically lower prices and higher volumes. Unitree’s G1/R1 platforms have dropped from ~$85,000 to $5,900–$16,000 in roughly two years through vertical integration (90%+ in-house components) and aggressive iteration.[12][13]

In 2025, Chinese firms (led by Unitree and AgiBot) accounted for ~80% of global humanoid shipments, with Unitree alone reportedly delivering thousands versus Figure’s ~150 units.[14][15]

The mechanism is straightforward: lower labor and component costs, state-supported manufacturing ecosystems, and a willingness to accept lower per-unit margins enable rapid volume that generates real-world data loops unavailable to Western players still focused on high-spec prototypes. This creates a two-tier market where price-sensitive early adopters (factories, logistics) may lock in with Chinese hardware before Figure’s superior AI/software can differentiate at scale.

Specific negative coverage and internal signals have emerged around Figure itself. A November 2025 whistleblower lawsuit by former product-safety head Robert Gruendel alleges the company rushed development, lacked formal safety procedures, and produced robots capable of “superhuman speed” and forces “twenty times higher than the threshold of pain”—including a malfunction that carved a quarter-inch gash in stainless steel—while dismissing safety concerns.[16][17]

Figure denies the claims and has reportedly countersued. Separately, a Fortune article questioned the scale of the BMW partnership (claiming fewer robots and smaller scope than portrayed), prompting Figure to threaten defamation litigation.[18]

WSJ reporting and analyst commentary have also tempered expectations, noting that even humanoid makers themselves view current systems as overhyped for complex industrial or domestic work.[19]

These incidents amplify investor and customer skepticism at a moment when credibility on safety and delivery timelines is critical.

Ranked top risks to Figure AI’s long-term viability (most to least severe, based on recurrence in failed predecessors and current evidence):

1. Failure to cross the “valley of death” from pilot to profitable scaled deployment — sustained high burn without recurring revenue or proven multi-site uptime will mirror Rethink/Sarcos outcomes.
2. Price/volume competition from Chinese players eroding addressable market — early adopters may standardize on sub-$10k hardware before Figure reaches competitive economics.
3. Safety/regulatory or reputational damage from whistleblower allegations or real incidents — high-power humanoids operating near people invite liability and customer hesitation.
4. Persistent sim-to-real and generalization gaps limiting reliability — without dramatic improvements in transfer learning, deployments remain labor-intensive and uneconomic.
5. Manufacturing yield and supply-chain scaling delays — custom actuators and immature component ecosystems could cap production velocity even if AI software succeeds.

These risks are interconnected; progress on any one (e.g., cheaper manufacturing) does not automatically solve the others. Competitors or new entrants must therefore prioritize narrow, high-margin niches with measurable ROI over general-purpose claims, while building robust safety validation and real-world data flywheels from day one.

---

Recent Findings Supplement (May 2026)

Figure AI faces mounting scrutiny over its BMW partnership and demo credibility, with recent coverage highlighting discrepancies between claims and verified operations. In June 2025, CEO Brett Adcock sidestepped direct questions about whether the BMW relationship had moved beyond a pilot into meaningful commercial revenue during a Bloomberg Tech conference appearance, offering only general comments on operational data collection while providing no contract specifics.[1][1] This followed earlier questions about overstated "fleet" deployments and "end-to-end operations," prompting Adcock to publicly threaten legal action against at least one critical report. The company was simultaneously pursuing a $1.5 billion raise at a $39.5 billion valuation despite limited disclosed revenue.[1]

• As of mid-2025 reporting referenced in 2025 coverage, BMW confirmed only limited single-robot tasks (parts handling in body shop) rather than broad fleet deployment.[2]
• Figure continued releasing videos while avoiding live demos at events where competitors like Agility and Boston Dynamics participated.[1]
• In May 2026, Adcock publicly defended a high-profile test against teleoperation skepticism, underscoring ongoing doubts about autonomous performance.[3]

This pattern suggests investors and partners must demand third-party-verified deployment metrics and revenue attribution rather than relying on founder statements or videos.

Rethink Robotics’ second shutdown in September 2025 exemplifies the recurring “valley of death” for humanoid-adjacent robotics startups, where early promise fails to scale commercially. The company, known for collaborative arms like Baxter and Sawyer, filed bankruptcy again after its 2018 collapse and subsequent acquisition; former CEO Julia Astrid Riemenschneider cited unready products, missed sales targets, and investor pullback.[4] Co-founder Rodney Brooks amplified this in a December 2025 New York Times interview, arguing the current Silicon Valley humanoid craze is “doomed to fail” due to flawed assumptions about rapid generalization from demos.[5]

• Brooks reiterated in 2026 commentary that robotics hardware lacks software’s exponential cost/performance gains, making hype-driven valuations unsustainable.[6]
• Broader 2025–2026 analyses note robotics startups frequently prove lab concepts but collapse on unit economics and reliability at volume.[7]

New entrants must prioritize proven, narrow-use-case deployments with clear payback periods over general-purpose ambitions to avoid Rethink’s fate.

Chinese competitors like Unitree are rapidly closing any perceived technology gap while undercutting on price and achieving manufacturing scale that Western firms have historically struggled to match. In 2025, China captured over 85% of roughly 15,000 global humanoid installations (versus 13% for the U.S.), with Unitree and peers driving the majority.[8] Unitree filed for a Shanghai STAR Market IPO in March 2026 targeting ~$7 billion valuation, reporting 60% gross margins and >5,500 humanoid shipments in 2025 (surpassing all U.S. competitors combined) while targeting 20,000 units in 2026.[9] Base pricing sits at $13,500–$15,400 per unit.[8]

• February 2026 Spring Festival Gala showcased Unitree robots performing fluid kung fu, flips, and fault recovery alongside humans—far more dynamic than prior years’ demos.[10]
• Multiple Chinese firms signaled U.S. market entry after strong CES 2026 showings.[11]

Western startups like Figure must demonstrate not just AI superiority but materially better economics or capabilities to justify premium pricing against this volume-driven threat.

Even Figure’s own April 2026 production update reveals persistent hardware and reliability hurdles that align with historical robotics pitfalls. The company described transitioning from prototype to scalable fleet as a “significant hurdle,” requiring supplier qualification for hundreds of parts, yield and cycle-time improvements, and addressing a “long tail” of edge-case failures only visible after accumulating substantial fleet operating hours.[12]

• Earlier demos drew teleoperation doubts, which the CEO addressed publicly in May 2026.[3]
• Expert commentary continues to flag inference, dexterity, and long-term reliability as open problems limiting use cases.[6]

This implies that pilot successes do not automatically translate to profitable, high-volume deployments without years of iterative, expensive real-world hardening.

Ranked top risks to Figure AI’s long-term viability (based on recency and specificity of evidence):

1. Sustained skepticism around commercial traction and hype vs. reality (e.g., BMW discrepancies and high-valuation raises with minimal revenue disclosure) eroding investor and customer confidence.
2. Aggressive Chinese price and volume competition (Unitree’s 2025–2026 shipments, margins, and IPO path) commoditizing the market before Figure reaches scale.
3. Recurring “valley of death” patterns demonstrated by Rethink’s 2025 shutdown and Brooks’ critiques of humanoid economics.
4. Hardware reliability and manufacturability gaps (long-tail failures, yield issues) delaying profitable deployment despite pilot progress.
5. Demo-to-real-world performance doubts (teleoperation concerns, limited live verification) undermining claims of general-purpose autonomy.